logo-loader
Shield Therapeutics PLC

Second Price Monitoring Extn

RNS Number : 9086G
Shield Therapeutics PLC
26 July 2019
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APMGMGZNFVKGLZM

Quick facts: Shield Therapeutics PLC

Price: £1.79

Market: LSE
Market Cap: £209.18 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics 'in a strong position' and confident of a US Feraccru deal

Shield Therapeutics (LON:STX) chief financial officer Tim Watts talks Proactive London's Andrew Scott through their first half update to June 2019. ''If you consider where we've been over the last 12 months we're in a far, far stronger position now and with the US approval of Feraccru we're...

1 week, 3 days ago

RNS

Director/PDMR Shareholding

3 days, 6 hours ago

Half-year Report

1 week, 4 days ago

Notice of Results

2 weeks, 4 days ago

Price Monitoring Extension

3 weeks, 2 days ago

Additional Listing

on 2/7/19

Result of AGM

on 13/6/19